HOLOGIC INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HOLOGIC INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $4.10B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $4.03B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $4.03B | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $4.86B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $5.63B | Nov 21, 2023 |
| FY2020 | Sep 26, 2020 | $1.35B | Nov 17, 2020 |
| FY2020 | Jun 27, 2020 | $822.90M | Nov 17, 2020 |
| FY2020 | Mar 28, 2020 | $756.10M | Nov 17, 2020 |
| FY2020 | Dec 28, 2019 | $850.50M | Nov 17, 2020 |
| FY2020 | Sep 28, 2019 | $865.80M | Nov 17, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $2.12B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $2.23B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $2.07B | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $3.00B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $3.80B | Nov 21, 2023 |
| FY2020 | Sep 26, 2020 | $931.80M | Nov 17, 2020 |
| FY2020 | Jun 27, 2020 | $466.10M | Nov 17, 2020 |
| FY2020 | Mar 28, 2020 | $395.80M | Nov 17, 2020 |
| FY2020 | Dec 28, 2019 | $433.80M | Nov 17, 2020 |
| FY2020 | Sep 28, 2019 | $249.50M | Nov 17, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $565.70M | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $789.50M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $456.00M | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $1.30B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $1.87B | Nov 21, 2023 |
| FY2020 | Sep 26, 2020 | $495.00M | Nov 17, 2020 |
| FY2020 | Jun 27, 2020 | $137.90M | Nov 17, 2020 |
| FY2020 | Mar 28, 2020 | $96.30M | Nov 17, 2020 |
| FY2020 | Dec 28, 2019 | $386.10M | Nov 17, 2020 |
| FY2020 | Sep 28, 2019 | ($123.50M) | Nov 17, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $714.30M | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $882.60M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $668.40M | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $1.64B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $2.48B | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | $1.11B | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | ($123.80M) | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | ($237.90M) | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | $1.37B | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | $548.60M | Nov 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $248.20M | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $272.80M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $294.30M | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $283.40M | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $276.30M | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | $222.50M | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | $232.20M | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | $218.70M | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | $232.80M | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | $232.10M | Nov 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $1.06B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $1.29B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $1.05B | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $2.13B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $2.33B | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | $896.60M | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | $649.50M | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | $732.90M | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | $8.30M | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | $798.20M | Nov 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $58.80M | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $72.40M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $91.80M | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $70.60M | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $118.30M | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | $98.30M | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | $57.00M | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | $58.40M | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | $57.80M | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | $47.30M | Nov 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $9.01B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $9.16B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $9.14B | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | $9.07B | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | $8.92B | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | $7.20B | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | $6.44B | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | $7.23B | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | $7.98B | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | $7.32B | Nov 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $5.05B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $5.13B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $5.02B | Nov 27, 2024 |
| FY2023 | Sep 24, 2022 | $4.88B | Nov 21, 2023 |
| FY2022 | Sep 25, 2021 | $4.22B | Nov 15, 2022 |
| FY2021 | Sep 26, 2020 | $2.71B | Nov 16, 2021 |
| FY2020 | Sep 28, 2019 | $2.12B | Nov 17, 2020 |
| FY2019 | Sep 29, 2018 | $2.43B | Nov 27, 2019 |
| FY2019 | Sep 30, 2017 | $2.78B | Nov 27, 2019 |
| FY2019 | Sep 24, 2016 | $2.14B | Nov 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $3.64B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $3.44B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $3.28B | Nov 27, 2024 |
| FY2023 | Sep 24, 2022 | $3.24B | Nov 21, 2023 |
| FY2022 | Sep 25, 2021 | $3.28B | Nov 15, 2022 |
| FY2021 | Sep 26, 2020 | $2.66B | Nov 16, 2021 |
| FY2020 | Sep 28, 2019 | $2.56B | Nov 17, 2020 |
| FY2019 | Sep 29, 2018 | $2.53B | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $3.17B | Nov 20, 2018 |
| FY2017 | Sep 24, 2016 | $2.80B | Nov 21, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $3.41B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $2.85B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $2.06B | Nov 27, 2024 |
| FY2023 | Sep 24, 2022 | $1.60B | Nov 21, 2023 |
| FY2022 | Sep 25, 2021 | $298.30M | Nov 15, 2022 |
| FY2021 | Sep 26, 2020 | ($1.57B) | Nov 16, 2021 |
| FY2020 | Sep 28, 2019 | ($2.69B) | Nov 17, 2020 |
| FY2019 | Sep 29, 2018 | ($2.49B) | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | ($2.38B) | Nov 20, 2018 |
| FY2017 | Sep 24, 2016 | ($3.14B) | Nov 21, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $1.96B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $2.16B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $2.72B | Nov 27, 2024 |
| FY2022 | Sep 24, 2022 | $2.34B | Nov 15, 2022 |
| FY2021 | Sep 25, 2021 | $1.17B | Nov 16, 2021 |
| FY2021 | Sep 26, 2020 | $701.00M | Nov 16, 2021 |
| FY2020 | Sep 28, 2019 | $601.80M | Nov 17, 2020 |
| FY2019 | Sep 29, 2018 | $666.70M | Nov 27, 2019 |
| FY2019 | Sep 30, 2017 | $540.60M | Nov 27, 2019 |
| FY2019 | Sep 24, 2016 | $548.40M | Nov 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $2.51B | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | $2.53B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $2.82B | Nov 27, 2024 |
| FY2023 | Sep 24, 2022 | $2.82B | Nov 21, 2023 |
| FY2022 | Sep 25, 2021 | $3.03B | Nov 15, 2022 |
| FY2021 | Sep 26, 2020 | $3.04B | Nov 16, 2021 |
| FY2020 | Sep 28, 2019 | $3.06B | Nov 17, 2020 |
| FY2019 | Sep 29, 2018 | $3.30B | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $3.32B | Nov 20, 2018 |
| FY2017 | Sep 24, 2016 | $3.35B | Nov 21, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 2 | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | 3 | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | 1 | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | 5 | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | 7 | Nov 21, 2023 |
| FY2022 | Sep 26, 2020 | 4 | Nov 15, 2022 |
| FY2021 | Sep 28, 2019 | 0 | Nov 16, 2021 |
| FY2020 | Sep 29, 2018 | 0 | Nov 17, 2020 |
| FY2019 | Sep 30, 2017 | 2 | Nov 27, 2019 |
| FY2018 | Sep 24, 2016 | 1 | Nov 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 2 | Nov 18, 2025 |
| FY2025 | Sep 28, 2024 | 3 | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | 1 | Nov 18, 2025 |
| FY2024 | Sep 24, 2022 | 5 | Nov 27, 2024 |
| FY2023 | Sep 25, 2021 | 7 | Nov 21, 2023 |
| FY2020 | Sep 26, 2020 | 1 | Nov 17, 2020 |
| FY2020 | Jun 27, 2020 | 0 | Nov 17, 2020 |
| FY2020 | Mar 28, 2020 | 0 | Nov 17, 2020 |
| FY2020 | Dec 28, 2019 | 1 | Nov 17, 2020 |
| FY2020 | Sep 28, 2019 | 0 | Nov 17, 2020 |